Shares of BioNano Genomics Inc (NASDAQ:BNGO) gapped up before the market opened on Tuesday . The stock had previously closed at $0.48, but opened at $0.47. BioNano Genomics shares last traded at $0.47, with a volume of 5,137,442 shares trading hands.
A number of analysts have commented on BNGO shares. Roth Capital restated a “buy” rating and set a $1.00 price target on shares of BioNano Genomics in a research note on Thursday, June 4th. Zacks Investment Research lowered shares of BioNano Genomics from a “hold” rating to a “sell” rating in a research note on Monday. Oppenheimer reiterated a “buy” rating and issued a $1.50 target price on shares of BioNano Genomics in a research note on Thursday, June 11th. Finally, Maxim Group reiterated a “buy” rating and issued a $3.00 target price on shares of BioNano Genomics in a research note on Wednesday, April 1st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $1.50.
The firm has a market capitalization of $38.93 million, a PE ratio of -0.24 and a beta of 1.49. The company’s fifty day simple moving average is $0.47 and its 200 day simple moving average is $0.73.
BioNano Genomics (NASDAQ:BNGO) last released its quarterly earnings data on Thursday, June 18th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.08). The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.10 million. BioNano Genomics had a negative net margin of 344.98% and a negative return on equity of 15,212.64%. Research analysts predict that BioNano Genomics Inc will post -0.46 EPS for the current year.
A hedge fund recently bought a new stake in BioNano Genomics stock. Geode Capital Management LLC purchased a new stake in shares of BioNano Genomics Inc (NASDAQ:BNGO) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 252,776 shares of the company’s stock, valued at approximately $313,000. Geode Capital Management LLC owned 0.95% of BioNano Genomics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.97% of the company’s stock.
About BioNano Genomics (NASDAQ:BNGO)
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Featured Story: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.